SEC Form 5 · accession 0001295345-17-000198
OWC Pharmaceutical Research Corp. · OWCP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mordechai Bignitz
Officer — CEO and Chairman · Director
Period of report
Dec 31, 2016
Accepted (ET)
Jun 22, 2017 · 1:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001431934
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionF1 | $0.05 | holding | — | — | — | Dec 15, 2016 | Dec 15, 2021 | Common Stock | 10,000,000 | 10,000,000 | D |
Explanation of responses
- F1On December 15, 2016, the Company granted Mr. Bignitz 10,000,000 options under the 2016 ESOP. The options are exercisable at $0.05 and are subject to the provisions of applicable Israeli laws. They are held by a trustee and may not be exercised and sold within the first two years after the date of grant. Nevertheless, these options vest 1/3 on the day of grant and 8.33% vest on a quarterly basis.